<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20241128011632&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20241128011632&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 28 Nov 2024 06:16:33 +0000</lastbuilddate>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Endocarditis Therapy: The Move From Expert Opinion to Evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2305-2307. doi: 10.1016/j.jacc.2024.07.063.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39603751</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.063>10.1016/j.jacc.2024.07.063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603751</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Brad Spellberg</dc:creator>
<dc:creator>Todd C Lee</dc:creator>
<dc:creator>Bassam Ghanem</dc:creator>
<dc:creator>Emily G McDonald</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Endocarditis Therapy: The Move From Expert Opinion to Evidence</dc:title>
<dc:identifier>pmid:39603751</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.063</dc:identifier>
</item>
<item>
<title>Length of Hospital Stay for Endocarditis Before and After the Partial Oral Treatment of Endocarditis Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Following the POET trial, we found a reduction in median LOS of 8 days with no change in mortality and an associated lower rate of relapse of bacteremia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2293-2304. doi: 10.1016/j.jacc.2024.06.053.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The results from the POET (Partial Oral Treatment of left-sided Endocarditis) trial were published in August 2018 and established noninferiority of oral step-down antibiotic treatment in stabilized patients with infective endocarditis (IE). Data on length of hospital stay (LOS) and safety following the POET trial are warranted.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to examine changes in LOS and safety (mortality and relapse of bacteremia) before and after POET publication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using Danish nationwide registries, patients with first-time IE caused by Streptococcus spp., Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci from 2012 to 2021 were identified. Median LOS was examined according to publication date (before and after September 2018). Mortality and relapse of bacteremia at 180 days of follow-up were examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified 3,008 patients before POET publication (median age 72.8 years) and 1,740 after publication (median age 75.2 years) (P &lt; 0.0001). The median LOS decreased by 8 days: 41 days (Q1-Q3: 29-49 days) before POET publication and 33 days (Q1-Q3: 21-44 days) after POET publication (P &lt; 0.0001). Similar reductions in LOS were seen across microbiological etiologies and age groups. Reduction in LOS was most pronounced in nonsurgically treated patients. Mortality from IE admission to a maximum of 180 days' follow-up was 27.5% before POET publication and 28.3% after publication (P = 0.41). The bacteremia relapse rate within 180 days was 3.5% before POET publication and 1.6% after publication (P = 0.0002).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Following the POET trial, we found a reduction in median LOS of 8 days with no change in mortality and an associated lower rate of relapse of bacteremia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39603750</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.053>10.1016/j.jacc.2024.06.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603750</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lauge Østergaard</dc:creator>
<dc:creator>Mia Marie Pries-Heje</dc:creator>
<dc:creator>Marianne Voldstedlund</dc:creator>
<dc:creator>Niels Eske Bruun</dc:creator>
<dc:creator>Jonas Agerlund Povlsen</dc:creator>
<dc:creator>Nana Køber</dc:creator>
<dc:creator>Nikolaj Ihlemann</dc:creator>
<dc:creator>Christian Tuxen</dc:creator>
<dc:creator>Rasmus Hasselbalch</dc:creator>
<dc:creator>Peter Godsk Jørgensen</dc:creator>
<dc:creator>Anna Stahl</dc:creator>
<dc:creator>Eva Havers-Borgersen</dc:creator>
<dc:creator>Jeppe Kofoed Petersen</dc:creator>
<dc:creator>Claus Moser</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Kasper Iversen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Emil Loldrup Fosbøl</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Length of Hospital Stay for Endocarditis Before and After the Partial Oral Treatment of Endocarditis Trial</dc:title>
<dc:identifier>pmid:39603750</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.053</dc:identifier>
</item>
<item>
<title>Should We Let AI-ECG Algorithms Take Over the Grading of Diastolic Dysfunction in Mitral Regurgitation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603749/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2290-2292. doi: 10.1016/j.jacc.2024.07.064.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603749/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39603749</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.064>10.1016/j.jacc.2024.07.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603749</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Márton Tokodi</dc:creator>
<dc:creator>Attila Kovács</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Should We Let AI-ECG Algorithms Take Over the Grading of Diastolic Dysfunction in Mitral Regurgitation?</dc:title>
<dc:identifier>pmid:39603749</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.064</dc:identifier>
</item>
<item>
<title>Using Electrocardiogram to Assess Diastolic Function and Prognosis in Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603748/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with significant MR, the grading of LVDF by AI-ECG is independently associated with all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2278-2289. doi: 10.1016/j.jacc.2024.06.054.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The determination of left ventricular diastolic function (LVDF) in patients with significant (≥moderate) mitral regurgitation (MR) poses a complex challenge. We recently validated an artificial intelligence-enabled electrocardiogram (AI-ECG) algorithm to estimate LVDF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the risk of all-cause mortality across AI-ECG LVDF-derived myocardial disease (MD) grades in MR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a retrospective study including all patients in the AI-ECG LVDF study testing group who underwent comprehensive transthoracic echocardiography confirming significant MR and electrocardiogram within 14 days of each other at the Mayo Clinic between September 2001 and April 2023. AI-ECG LVDF status was determined based on the index electrocardiogram and used to categorize patients into 3 stages of MD: MD-1, normal or grade 1 LVDF; MD-2, grade 2 LVDF; and MD-3, grade 3 LVDF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4,019 patients with significant MR (mean age 69.8 years; 49.0% women), 1,175 (29.2%), 1,881 (46.8%), and 963 (24.0%) were classified by AI-ECG as MD-1, MD-2, and MD-3, respectively. The median mitral effective regurgitant orifice area was 26 mm<sup>2</sup> (Q1-Q3: 20-36 mm<sup>2</sup>). Over a median follow-up of 3.5 years, 1,636 (40.7%) patients died. In multivariable survival analysis adjusted for multiple risk factors, a higher diastolic function grade was independently associated with an increased death risk (MD-2, adjusted HR [aHR]: 1.99; 95% CI: 1.62-2.45; MD-3, aHR: 2.65; 95% CI: 2.11-3.34). These findings were consistent when accounting for mitral valve intervention and across various sensitivity and subgroup analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with significant MR, the grading of LVDF by AI-ECG is independently associated with all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603748/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39603748</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.054>10.1016/j.jacc.2024.06.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603748</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gal Tsaban</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Samual Wopperer</dc:creator>
<dc:creator>Muhannad Abbasi</dc:creator>
<dc:creator>Hee Tae Yu</dc:creator>
<dc:creator>Garvan C Kane</dc:creator>
<dc:creator>Francisco Lopez-Jimenez</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Vuyisile T Nkomo</dc:creator>
<dc:creator>Abhishek J Deshmukh</dc:creator>
<dc:creator>Samuel J Asirvatham</dc:creator>
<dc:creator>Peter A Noseworthy</dc:creator>
<dc:creator>Paul A Friedman</dc:creator>
<dc:creator>Zachi Attia</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Electrocardiogram to Assess Diastolic Function and Prognosis in Mitral Regurgitation</dc:title>
<dc:identifier>pmid:39603748</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.054</dc:identifier>
</item>
<item>
<title>The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603747/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2260-2263. doi: 10.1016/j.jacc.2024.07.057.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603747/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39603747</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.057>10.1016/j.jacc.2024.07.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603747</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?</dc:title>
<dc:identifier>pmid:39603747</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.057</dc:identifier>
</item>
<item>
<title>2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Individuals with T2DM had 2-fold more CVD events than matched comparisons starting 3 decades before T2DM diagnosis. This indicates that comprehensive preventive strategies may be initiated much earlier in individuals at risk of T2DM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2251-2259. doi: 10.1016/j.jacc.2024.06.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The risk of cardiovascular disease (CVD) is increased in individuals with type 2 diabetes mellitus (T2DM), but it remains uncertain how long an elevated CVD occurrence precedes diabetes diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to investigate CVD occurrence 30 years before, and 5 years after, T2DM diagnosis compared with matched comparisons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This combined case-control and cohort study included all individuals diagnosed with T2DM in Denmark between 2010 and 2015, as well as general population comparisons matched by age and sex. CVD was defined as myocardial infarction or ischemic stroke. Conditional logistic regression was used to compute ORs for CVD prevalence in the 30-year period before T2DM diagnosis. Cox proportional hazards regression models were used to compute HRs for 5-year CVD incidence after T2DM diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 127,092 individuals with T2DM and 381,023 matched comparisons. In the 30-year period before T2DM diagnosis, 14,179 (11.2%) T2DM individuals and 17,871 (4.7%) comparisons experienced CVD. CVD prevalence was higher in those with T2DM than the comparisons in the entire period before T2DM diagnosis, with ORs ranging from 2.18 (95% CI: 1.91-2.48) in the earliest period (25-30 years before diagnosis) to 2.96 (95% CI: 2.85-3.08) in the latest period (&lt;5 years before diagnosis). After T2DM diagnosis, 5-year CVD incidence was similarly increased in T2DM individuals vs comparisons (HR: 2.20; 95% CI: 2.12-2.27).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Individuals with T2DM had 2-fold more CVD events than matched comparisons starting 3 decades before T2DM diagnosis. This indicates that comprehensive preventive strategies may be initiated much earlier in individuals at risk of T2DM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39603746</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.050>10.1016/j.jacc.2024.06.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603746</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Johnny Kahlert</dc:creator>
<dc:creator>Pernille G Thrane</dc:creator>
<dc:creator>Kevin K W Olesen</dc:creator>
<dc:creator>Martin B Mortensen</dc:creator>
<dc:creator>Henrik T Sørensen</dc:creator>
<dc:creator>Reimar W Thomsen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study</dc:title>
<dc:identifier>pmid:39603746</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.050</dc:identifier>
</item>
<item>
<title>Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603238/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 26:S0092-8674(24)01339-4. doi: 10.1016/j.cell.2024.11.023. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603238/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39603238</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.023>10.1016/j.cell.2024.11.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603238</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>María Ramos Zapatero</dc:creator>
<dc:creator>Alexander Tong</dc:creator>
<dc:creator>James W Opzoomer</dc:creator>
<dc:creator>Rhianna O'Sullivan</dc:creator>
<dc:creator>Ferran Cardoso Rodriguez</dc:creator>
<dc:creator>Jahangir Sufi</dc:creator>
<dc:creator>Petra Vlckova</dc:creator>
<dc:creator>Callum Nattress</dc:creator>
<dc:creator>Xiao Qin</dc:creator>
<dc:creator>Jeroen Claus</dc:creator>
<dc:creator>Daniel Hochhauser</dc:creator>
<dc:creator>Smita Krishnaswamy</dc:creator>
<dc:creator>Christopher J Tape</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses</dc:title>
<dc:identifier>pmid:39603238</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.023</dc:identifier>
</item>
<item>
<title>Ablation of persistent atrial fibrillation: lessons learnt from the CAPLA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39602598/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae832. doi: 10.1093/eurheartj/ehae832. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39602598/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39602598</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae832>10.1093/eurheartj/ehae832</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39602598</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jayanthi N Koneru</dc:creator>
<dc:creator>Kenneth A Ellenbogen</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ablation of persistent atrial fibrillation: lessons learnt from the CAPLA trial</dc:title>
<dc:identifier>pmid:39602598</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae832</dc:identifier>
</item>
<item>
<title>Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39602157/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this study, in patients who experienced PCI and were event-free during 6 to 18 months of DAPT, the beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent, regardless of bleeding risk and/or PCI complexity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 27. doi: 10.1001/jamacardio.2024.4030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Antiplatelet monotherapy in the chronic maintenance period for patients with high bleeding risk (HBR) and those who have undergone complex percutaneous coronary intervention (PCI) has not yet been explored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare clopidogrel vs aspirin monotherapy in patients with HBR and/or PCI complexity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the multicenter HOST-EXAM Extended study, an open-label trial conducted across 37 sites in South Korea, enrolled patients from 2014 to 2018 with up to 5.9 years of follow-up. The analysis was conducted from February to November 2023. Patients who maintained dual antiplatelet therapy (DAPT) event-free for 6 to 18 months following PCI were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized to receive either clopidogrel or aspirin in a 1:1 ratio. Those with sufficient data to assess HBR or complex PCI were analyzed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Coprimary end points were thrombotic composite end point (cardiovascular death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and definite/probable stent thrombosis) and any bleeding (Bleeding Academic Research Consortium type 2 to 5).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 3974 patients included (mean [SD] age, 63.4 [10.7] years; 2976 male [74.9%]), 866 had HBR (21.8%), and 849 underwent complex PCI (21.4%). Clopidogrel as compared with aspirin was associated with lower rates of thrombotic and bleeding events regardless of HBR and/or PCI complexity. For the thrombotic composite end point, the hazard ratio (HR) was 0.75 (95% CI, 0.53-1.04) among HBR vs 0.62 (95% CI, 0.48-0.80) among patients without HBR (P for interaction = 0.38) and 0.49 (95% CI, 0.32-0.77) among patients with complex PCI vs 0.74 (95% CI, 0.59-0.92) among patients with noncomplex PCI (P for interaction = 0.12). The reduction in bleeding by clopidogrel compared with aspirin was consistent among both patients with HBR (HR, 0.82; 95% CI, 0.56-1.21) and patients without HBR (HR, 0.58; 95% CI, 0.40-0.85; P for interaction = 0.20) and among patients undergoing complex PCI (HR, 0.79; 95% CI, 0.47-1.33) vs noncomplex PCI (HR, 0.68; 95% CI, 0.50-0.93; P for interaction = 0.62).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, in patients who experienced PCI and were event-free during 6 to 18 months of DAPT, the beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent, regardless of bleeding risk and/or PCI complexity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02044250.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39602157/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39602157</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4030>10.1001/jamacardio.2024.4030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39602157</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jeehoon Kang</dc:creator>
<dc:creator>Jaewook Chung</dc:creator>
<dc:creator>Kyung Woo Park</dc:creator>
<dc:creator>Jang-Whan Bae</dc:creator>
<dc:creator>Huijin Lee</dc:creator>
<dc:creator>Doyeon Hwang</dc:creator>
<dc:creator>Han-Mo Yang</dc:creator>
<dc:creator>Kyoo-Rok Han</dc:creator>
<dc:creator>Keon-Woong Moon</dc:creator>
<dc:creator>Ung Kim</dc:creator>
<dc:creator>Moo-Yong Rhee</dc:creator>
<dc:creator>Doo-Il Kim</dc:creator>
<dc:creator>Song-Yi Kim</dc:creator>
<dc:creator>Sung-Yun Lee</dc:creator>
<dc:creator>Seung Uk Lee</dc:creator>
<dc:creator>Sang-Wook Kim</dc:creator>
<dc:creator>Seok Yeon Kim</dc:creator>
<dc:creator>Jung-Kyu Han</dc:creator>
<dc:creator>Eun-Seok Shin</dc:creator>
<dc:creator>Bon-Kwon Koo</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity</dc:title>
<dc:identifier>pmid:39602157</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4030</dc:identifier>
</item>
<item>
<title>The FINE ART of Interpreting Health Status Benefits in Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26:S0735-1097(24)10293-8. doi: 10.1016/j.jacc.2024.10.095. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39601741</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.095>10.1016/j.jacc.2024.10.095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601741</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The FINE ART of Interpreting Health Status Benefits in Clinical Trials</dc:title>
<dc:identifier>pmid:39601741</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.095</dc:identifier>
</item>
<item>
<title>Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae782. doi: 10.1093/eurheartj/ehae782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Almost 30% of survivors of myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria. Organelle quality control through Parkin-mediated mitochondrial autophagy (mitophagy) is known to play a role in mediating protection against HF damage post-ischaemic injury and remodelling of the subsequent deteriorated myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study has shown that a single i.p. dose (2 h post-MI) of the selective small molecule Parkin activator PR-364 reduced mortality, preserved cardiac ejection fraction, and mitigated the progression of HF. To reveal the mechanism of PR-364, a multi-omic strategy was deployed in combination with classical functional assays using in vivo MI and in vitro cardiomyocyte models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In vitro cell data indicated that Parkin activation by PR-364 increased mitophagy and mitochondrial biogenesis, enhanced adenosine triphosphate production via improved citric acid cycle, altered accumulation of calcium localization to the mitochondria, and initiated translational reprogramming with increased expression of mitochondrial translational proteins. In mice, PR-364 administered post-MI resulted in widespread proteome changes, indicating an up-regulation of mitochondrial metabolism and mitochondrial translation in the surviving myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrates the therapeutic potential of targeting Parkin-mediated mitophagy using PR-364 to protect surviving cardiac tissue post-MI from progression to HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39601359</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae782>10.1093/eurheartj/ehae782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601359</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lizhuo Ai</dc:creator>
<dc:creator>Juliana de Freitas Germano</dc:creator>
<dc:creator>Chengqun Huang</dc:creator>
<dc:creator>Marianne Aniag</dc:creator>
<dc:creator>Savannah Sawaged</dc:creator>
<dc:creator>Jon Sin</dc:creator>
<dc:creator>Reetu Thakur</dc:creator>
<dc:creator>Deepika Rai</dc:creator>
<dc:creator>Christopher Rainville</dc:creator>
<dc:creator>David E Sterner</dc:creator>
<dc:creator>Yang Song</dc:creator>
<dc:creator>Honit Piplani</dc:creator>
<dc:creator>Suresh Kumar</dc:creator>
<dc:creator>Tauseef R Butt</dc:creator>
<dc:creator>Robert M Mentzer</dc:creator>
<dc:creator>Aleksandr Stotland</dc:creator>
<dc:creator>Roberta A Gottlieb</dc:creator>
<dc:creator>Jennifer E Van Eyk</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364</dc:title>
<dc:identifier>pmid:39601359</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae782</dc:identifier>
</item>
<item>
<title>Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601339/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Coronary artery bypass grafting is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 27:ehae700. doi: 10.1093/eurheartj/ehae700. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The long-term outcomes of percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain debated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry was used to analyse 57 097 revascularized patients with NSTEMI with multivessel disease in Sweden from January 2005 to June 2022. The primary endpoint was all-cause mortality, encompassing both in-hospital and long-term mortality; the secondary endpoints included myocardial infarction (MI), stroke, new revascularization, and heart failure. Multilevel logistic regression with follow-up time as a log-transformed offset variable and double-robust adjustment with the instrumental variable method were applied to control for known and unknown confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Percutaneous coronary intervention was the primary therapy in 42 190 (73.9%) patients, while 14 907 (26.1%) received CABG. Percutaneous coronary intervention patients were generally older with more prior cardiovascular events, whereas CABG patients had higher incidences of diabetes, hypertension, left main and three-vessel disease, and reduced ejection fraction. Over a median follow-up of 7.1 years, PCI was associated with higher risks of death [adjusted odds ratio (aOR) 1.67; 95% confidence interval (CI) 1.54-1.81] and MI (aOR 1.51; 95% CI 1.41-1.62) but there was no significant difference in stroke. Repeat revascularization was three times more likely to PCI (aOR 3.01; 95% CI 2.57-3.51), while heart failure risk was 15% higher (aOR 1.15; 95% CI 1.07-1.25). Coronary artery bypass grafting provided longer survival within 15 years, especially in patients under 70 years of age, with left main disease or left ventricular dysfunction, though this benefit diminished over shorter time horizons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Coronary artery bypass grafting is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601339/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39601339</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae700>10.1093/eurheartj/ehae700</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601339</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Elmir Omerovic</dc:creator>
<dc:creator>Truls Råmunddal</dc:creator>
<dc:creator>Petur Petursson</dc:creator>
<dc:creator>Oskar Angerås</dc:creator>
<dc:creator>Araz Rawshani</dc:creator>
<dc:creator>Sandeep Jha</dc:creator>
<dc:creator>Kristofer Skoglund</dc:creator>
<dc:creator>Moman A Mohammad</dc:creator>
<dc:creator>Jonas Persson</dc:creator>
<dc:creator>Joakim Alfredsson</dc:creator>
<dc:creator>Robin Hofmann</dc:creator>
<dc:creator>Tomas Jernberg</dc:creator>
<dc:creator>Ole Fröbert</dc:creator>
<dc:creator>Anders Jeppsson</dc:creator>
<dc:creator>Emma C Hansson</dc:creator>
<dc:creator>Göran Dellgren</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry</dc:title>
<dc:identifier>pmid:39601339</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae700</dc:identifier>
</item>
<item>
<title>Social Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601150/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results identify a novel brain-liver axis that links sociality to hepatic lipid metabolism, thus proposing a potential therapeutic strategy for loneliness-associated atherosclerosis progression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Nov 27. doi: 10.1161/CIRCRESAHA.124.324638. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUNDS: Social interaction with others is essential to life. Although social isolation and loneliness have been implicated as increased risks of cardiometabolic and cardiovascular diseases and all-cause mortality, the cellular and molecular mechanisms by which social connection maintains cardiometabolic and cardiovascular health remain largely unresolved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To investigate how social connection protects against cardiometabolic and cardiovascular diseases, atherosclerosis-prone, high-fat diet-fed <i>Apoe</i><sup>-/-</sup> mouse siblings were randomly assigned to either individual or grouped housing for 12 weeks. Histological, flow cytometric, biochemical, gene, and protein analyses were performed to assess atherosclerotic lesions, systemic metabolism, inflammation, and stress response. The effects of oxytocin on hepatocytes and subsequent cardiometabolic and cardiovascular function were investigated by in vivo and in vitro approaches.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>Apoe</i><sup>-/-</sup> mice housed individually developed larger vulnerable atherosclerotic lesions by disrupted lipid metabolism compared with those of mice in regular group housing, irrespective of body weight, eating behavior, feeding conditions, sympathetic nervous activity, glucocorticoid response, or systemic inflammation. Mechanistically, the chronic isolation reduced the hypothalamic production of oxytocin, which controls bile acid production and LPL (lipoprotein lipase) activity through the peripheral OXTR (oxytocin receptor) in hepatocytes, whose downstream targets include <i>Cyp7a1</i>, <i>Angptl4</i>, and <i>Angptl8</i>. While hepatocyte-specific OXTR-null mice and mice receiving adeno-associated virus targeting OXTR on hepatocytes led to severe dyslipidemia and aggravated atherosclerosis, oral oxytocin supplementation to socially isolated mice, but not to hepatocyte-specific OXTR conditional knockout mice, improved lipid profiles and retarded atherosclerosis development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results identify a novel brain-liver axis that links sociality to hepatic lipid metabolism, thus proposing a potential therapeutic strategy for loneliness-associated atherosclerosis progression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601150/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39601150</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324638>10.1161/CIRCRESAHA.124.324638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601150</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Seien Ko</dc:creator>
<dc:creator>Atsushi Anzai</dc:creator>
<dc:creator>Xueyuan Liu</dc:creator>
<dc:creator>Kenichiro Kinouchi</dc:creator>
<dc:creator>Kazuhiro Yamanoi</dc:creator>
<dc:creator>Takuto Torimitsu</dc:creator>
<dc:creator>Genki Ichihara</dc:creator>
<dc:creator>Hiroki Kitakata</dc:creator>
<dc:creator>Kohsuke Shirakawa</dc:creator>
<dc:creator>Yoshinori Katsumata</dc:creator>
<dc:creator>Jin Endo</dc:creator>
<dc:creator>Kaori Hayashi</dc:creator>
<dc:creator>Masahide Yoshida</dc:creator>
<dc:creator>Katsuhiko Nishimori</dc:creator>
<dc:creator>Kenji F Tanaka</dc:creator>
<dc:creator>Tatsushi Onaka</dc:creator>
<dc:creator>Motoaki Sano</dc:creator>
<dc:creator>Masaki Ieda</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Social Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis</dc:title>
<dc:identifier>pmid:39601150</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324638</dc:identifier>
</item>
<item>
<title>Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results demonstrate that neutrophil CRACR2A promotes neutrophil recruitment to sites of sterile inflammation, such as ischemic stroke. Blocking the STIM1-CRACR2A interaction may be a novel therapeutic strategy to mitigate inflammation and consequent tissue injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 27. doi: 10.1161/CIRCULATIONAHA.124.070487. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> channel regulator 2A (CRACR2A) has been linked to immunodeficiency attributable to T-cell dysfunction in humans. We discovered that neutrophil CRACR2A promotes neutrophil adhesive and migratory functions by facilitating Ca<sup>2+</sup> mobilization and β2 integrin activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Myeloid-specific cracr2a conditional knockout mice and intravital microscopy were used to investigate the physiologic role of neutrophil cracr2a in neutrophil recruitment in vascular inflammation. Cracr2a-deficient neutrophils or dHL-60 (differentiated human neutrophil-like) cells and CRACR2A-derived peptides were used in flow cytometry, immunoprecipitation, cytosolic Ca<sup>2+</sup> mobilization, and flow chamber assays to elucidate the molecular mechanism. Four-dimensional confocal intravital microscopy of mice after focal brain ischemia and single neutrophil behavioral analysis demonstrated the pathologic role of neutrophil cracr2a in brain damage.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with wild-type control mice, cracr2a conditional knockout mice exhibited significantly reduced adhesion, crawling, and transmigration of neutrophils on ear and cremaster venules in tumor necrosis factor-α-induced sterile inflammation. Neutrophil cracr2a rapidly interacts with STIM1 (stromal interaction molecule 1) after agonist stimulation and facilitates Ca<sup>2+</sup> mobilization, increasing the ligand-binding function of β2 integrin. Our findings in cracr2a-deficient mouse neutrophils are recapitulated in dHL-60 cells, in which CRACR2A is deleted by CRISPR/Cas9. Furthermore, overexpression of CRACR2A in CRACR2A KO dHL-60 cells restores normal function. Using a series of peptides covering the coiled-coil region of CRACR2A, we identified a palmitoylated 20-mer that blocks STIM1-CRACR2A interaction. Treating neutrophils with this 20-mer inhibits Ca<sup>2+</sup> mobilization and β2 integrin activation after agonist stimulation, reducing neutrophil recruitment to an activated endothelial cell monolayer under venous shear stress and to ear venules in tumor necrosis factor-α-challenged mice. Cerebral 4-dimensional intravital microscopy of mice after focal brain ischemia revealed that neutrophil cracr2a enhances the emergence of highly migratory neutrophils by increasing the surface level of αMβ2 integrin, thereby facilitating neutrophil infiltration into brain tissue and exacerbating brain injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results demonstrate that neutrophil CRACR2A promotes neutrophil recruitment to sites of sterile inflammation, such as ischemic stroke. Blocking the STIM1-CRACR2A interaction may be a novel therapeutic strategy to mitigate inflammation and consequent tissue injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39601147</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070487>10.1161/CIRCULATIONAHA.124.070487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601147</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jingu Lee</dc:creator>
<dc:creator>Brett Balzraine</dc:creator>
<dc:creator>Alexis Schweizer</dc:creator>
<dc:creator>Vasilisa Kuzmanova</dc:creator>
<dc:creator>Yousang Gwack</dc:creator>
<dc:creator>Babak Razani</dc:creator>
<dc:creator>Jin-Moo Lee</dc:creator>
<dc:creator>Deane F Mosher</dc:creator>
<dc:creator>Jaehyung Cho</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke</dc:title>
<dc:identifier>pmid:39601147</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070487</dc:identifier>
</item>
<item>
<title>Declining Trend of Sudden Cardiac Death in Younger Individuals: A 20-Year Nationwide Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39601123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SCD incidence rates in young individuals declined by 49% over the past 2 decades. The decline was paralleled by improved survival of OHCA, higher diagnostic rates of inherited cardiac diseases, and higher ICD implantation rates. However, rates of unwitnessed SCD were unchanged, which calls for new perspectives in preventive strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 27. doi: 10.1161/CIRCULATIONAHA.124.069431. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Declining cardiovascular mortality rates have been well-documented, yet temporal trends of sudden cardiac death (SCD) in young individuals remain unclear. We provide contemporary nationwide estimates of the temporal trends of SCD in young individuals (1-35 years of age) from 2000 through 2019 and correlate these trends to changes in out-of-hospital cardiac arrest (OHCA) patterns, rates of inherited cardiac diseases, and implantations of implantable cardioverter defibrillators (ICD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All individuals between 1 and 35 years of age living in Denmark from 2000 through 2019 were included, with annual re-evaluation of the at-risk population in regard to age. Adjudication of SCD cases relied on multiple sources, including death certificates, medical files, and autopsy reports. Information on OHCA, diagnostic rates, and ICD implantations were captured from nationwide administrative registries. Annual incidence rates of SCD were calculated, and temporal trends in SCD incidence were computed as percentage change annualized. Trends in OHCA survival and characteristics, diagnostic rates of inherited cardiac diseases, and ICD implantations were assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the 20-year study period (47.5 million person-years), 1057 SCDs were identified (median age, 29 years; 69% male). The overall incidence of SCD was 2.2 per 100 000 person-years and declined by 3.31% (95% CI, 2.42-4.20) annually, corresponding to a 49% (95% CI, 38.7-57.6) reduction during the study. Rates of witnessed SCD declined markedly (percentage change annualized -7.03% [95% CI, -8.57 to -5.48]), but we observed no changes in the rate of unwitnessed SCD (percentage change annualized -0.09% [95% CI, -1.48 to 1.31]). Therefore, the proportion of unwitnessed SCD increased by 79% (<i>P</i>&lt;0.001). Survival after OHCA in young individuals (1 to 35 years of age) increased from 3.9% to 28%, mainly because of increased bystander cardiopulmonary resuscitation and defibrillation rates. Diagnostic rates of inherited cardiac diseases increased 10-fold (incidence rate ratio, 10.4 [95% CI, 8.46-12.90]) and the ICD implantation rate increased 2-fold (incidence rate ratio, 1.97 [95% CI, 1.51-2.60]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SCD incidence rates in young individuals declined by 49% over the past 2 decades. The decline was paralleled by improved survival of OHCA, higher diagnostic rates of inherited cardiac diseases, and higher ICD implantation rates. However, rates of unwitnessed SCD were unchanged, which calls for new perspectives in preventive strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39601123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39601123</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069431>10.1161/CIRCULATIONAHA.124.069431</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39601123</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Carl Johann Hansen</dc:creator>
<dc:creator>Jesper Svane</dc:creator>
<dc:creator>Peder Emil Warming</dc:creator>
<dc:creator>Thomas Hadberg Lynge</dc:creator>
<dc:creator>Rodrigue Garcia</dc:creator>
<dc:creator>Carolina Malta Hansen</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Jytte Banner</dc:creator>
<dc:creator>Bo Gregers Winkel</dc:creator>
<dc:creator>Jacob Tfelt-Hansen</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Declining Trend of Sudden Cardiac Death in Younger Individuals: A 20-Year Nationwide Study</dc:title>
<dc:identifier>pmid:39601123</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069431</dc:identifier>
</item>
<item>
<title>Mechano-dependent sorbitol accumulation supports biomolecular condensate</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39591966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>Condensed droplets of protein regulate many cellular functions, yet the physiological conditions regulating their formation remain largely unexplored. Increasing our understanding of these mechanisms is paramount, as failure to control condensate formation and dynamics can lead to many diseases. Here, we provide evidence that matrix stiffening promotes biomolecular condensation in vivo. We demonstrate that the extracellular matrix links mechanical cues with the control of glucose metabolism to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 16:S0092-8674(24)01271-6. doi: 10.1016/j.cell.2024.10.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Condensed droplets of protein regulate many cellular functions, yet the physiological conditions regulating their formation remain largely unexplored. Increasing our understanding of these mechanisms is paramount, as failure to control condensate formation and dynamics can lead to many diseases. Here, we provide evidence that matrix stiffening promotes biomolecular condensation in vivo. We demonstrate that the extracellular matrix links mechanical cues with the control of glucose metabolism to sorbitol. In turn, sorbitol acts as a natural crowding agent to promote biomolecular condensation. Using in silico simulations and in vitro assays, we establish that variations in the physiological range of sorbitol concentrations, but not glucose concentrations, are sufficient to regulate biomolecular condensates. Accordingly, pharmacological and genetic manipulation of intracellular sorbitol concentration modulates biomolecular condensates in breast cancer-a mechano-dependent disease. We propose that sorbitol is a mechanosensitive metabolite enabling protein condensation to control mechano-regulated cellular functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39591966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39591966</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.048>10.1016/j.cell.2024.10.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39591966</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephanie Torrino</dc:creator>
<dc:creator>William M Oldham</dc:creator>
<dc:creator>Andrés R Tejedor</dc:creator>
<dc:creator>Ignacio S Burgos</dc:creator>
<dc:creator>Lara Nasr</dc:creator>
<dc:creator>Nesrine Rachedi</dc:creator>
<dc:creator>Kéren Fraissard</dc:creator>
<dc:creator>Caroline Chauvet</dc:creator>
<dc:creator>Chaima Sbai</dc:creator>
<dc:creator>Brendan P O'Hara</dc:creator>
<dc:creator>Sophie Abélanet</dc:creator>
<dc:creator>Frederic Brau</dc:creator>
<dc:creator>Cyril Favard</dc:creator>
<dc:creator>Stephan Clavel</dc:creator>
<dc:creator>Rosana Collepardo-Guevara</dc:creator>
<dc:creator>Jorge R Espinosa</dc:creator>
<dc:creator>Issam Ben-Sahra</dc:creator>
<dc:creator>Thomas Bertero</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechano-dependent sorbitol accumulation supports biomolecular condensate</dc:title>
<dc:identifier>pmid:39591966</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.048</dc:identifier>
</item>
<item>
<title>ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39591965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>Metastatic dissemination to distant organs demands that cancer cells possess high morphological and metabolic adaptability. However, contributions of the cellular lipidome to metastasis remain elusive. Here, we uncover a correlation between metastasis potential and ferroptosis susceptibility in multiple cancers. Metastases-derived cancer cells exhibited higher ferroptosis sensitivity and polyunsaturated fatty acyl (PUFA)-lipid contents than primary-tumor-derived cells from ovarian cancer...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 19:S0092-8674(24)01270-4. doi: 10.1016/j.cell.2024.10.047. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Metastatic dissemination to distant organs demands that cancer cells possess high morphological and metabolic adaptability. However, contributions of the cellular lipidome to metastasis remain elusive. Here, we uncover a correlation between metastasis potential and ferroptosis susceptibility in multiple cancers. Metastases-derived cancer cells exhibited higher ferroptosis sensitivity and polyunsaturated fatty acyl (PUFA)-lipid contents than primary-tumor-derived cells from ovarian cancer patients. Metabolism-focused CRISPR screens in a mouse model for ovarian cancer distant metastasis established via two rounds of in vivo selection revealed the PUFA-lipid biosynthesis enzyme acyl-coenzyme A (CoA) synthetase long-chain family member 4 (ACSL4) as a pro-hematogenous metastasis factor. ACSL4 promotes metastatic extravasation by enhancing membrane fluidity and cellular invasiveness. While promoting metastasis, the high PUFA-lipid state creates dependencies on abhydrolase-domain-containing 6, acylglycerol lipase (ABHD6), enoyl-CoA delta isomerase 1 (ECI1), and enoyl-CoA hydratase 1 (ECH1)-rate-limiting enzymes preparing unsaturated fatty acids (UFAs) for β-oxidation. ACSL4/ECH1 co-inhibition achieved potent suppression of metastasis. Our work establishes the dual functions of PUFA-lipids in tumor progression and metastasis that may be exploitable for therapeutic development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39591965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39591965</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.047>10.1016/j.cell.2024.10.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39591965</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuqi Wang</dc:creator>
<dc:creator>Mangze Hu</dc:creator>
<dc:creator>Jian Cao</dc:creator>
<dc:creator>Fengxiang Wang</dc:creator>
<dc:creator>Jingrong Regina Han</dc:creator>
<dc:creator>Tianshu William Wu</dc:creator>
<dc:creator>Luxiao Li</dc:creator>
<dc:creator>Jinshi Yu</dc:creator>
<dc:creator>Yujing Fan</dc:creator>
<dc:creator>Guanglei Xie</dc:creator>
<dc:creator>Heyuan Lian</dc:creator>
<dc:creator>Yueying Cao</dc:creator>
<dc:creator>Nathchar Naowarojna</dc:creator>
<dc:creator>Xi Wang</dc:creator>
<dc:creator>Yilong Zou</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization</dc:title>
<dc:identifier>pmid:39591965</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.047</dc:identifier>
</item>
<item>
<title>Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39589540/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Accelerated pacing acutely reduces left-heart filling pressure in patients undergoing AF catheter ablation and computer simulations with HFpEF features, suggesting it as a potential therapeutic strategy to alleviate congestion symptoms. Virtual HFpEF patient cohorts hypothesize that AV sequential pacing may further optimize this therapy's beneficial effects.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 26:ehae718. doi: 10.1093/eurheartj/ehae718. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Accelerated atrial pacing offers potential benefits for patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF), compared with standard lower-rate pacing. The study investigates the relationship between atrial pacing rate and left-heart filling pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Seventy-five consecutive patients undergoing catheter ablation for AF underwent assessment of mean left atrial pressure (mLAP) and atrioventricular (AV) conduction delay (PR interval) in sinus rhythm and accelerated atrial pacing with 10 bpm increments up to Wenckebach block. Computer simulations (CircAdapt) of a virtual HFpEF cohort complemented clinical observations and hypothesized the modulating effects of AV coupling and atrial (dys)function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the study cohort, 49(65%) patients had a high HFpEF likelihood (H2FPEF ≥ 5.0), and 28(37%) an elevated mLAP ≥ 15 mmHg at sinus rhythm. Optimal pacing rates of 100 [70-110]bpm (median [IQR]) significantly reduced mLAP from 12.8 [10.0-17.4]mmHg in sinus rhythm (55 [52-61]bpm) to 10.4 [7.8-14.8]mmHg (P &lt; .001). Conversely, higher pacing rates (130 [110-140]bpm) significantly increased mLAP to 14.7 [11.0-17.8]mmHg (P &lt; .05). PR interval and, hence, AV conduction delay prolonged incrementally with increasing pacing rates. Simulations corroborated these clinical findings, showing mLAP reduction at a moderately increased pacing rate and a subsequent increase at higher rates. Moreover, simulations suggested that mLAP reduction is optimized when AV conduction delay shortens with increasing rate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Accelerated pacing acutely reduces left-heart filling pressure in patients undergoing AF catheter ablation and computer simulations with HFpEF features, suggesting it as a potential therapeutic strategy to alleviate congestion symptoms. Virtual HFpEF patient cohorts hypothesize that AV sequential pacing may further optimize this therapy's beneficial effects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39589540/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39589540</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae718>10.1093/eurheartj/ehae718</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39589540</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tim van Loon</dc:creator>
<dc:creator>Jesse Rijks</dc:creator>
<dc:creator>Johan van Koll</dc:creator>
<dc:creator>Joey Wolffs</dc:creator>
<dc:creator>Richard Cornelussen</dc:creator>
<dc:creator>Nick van Osta</dc:creator>
<dc:creator>Justin Luermans</dc:creator>
<dc:creator>Frits Prinzen</dc:creator>
<dc:creator>Dominik Linz</dc:creator>
<dc:creator>Vanessa van Empel</dc:creator>
<dc:creator>Tammo Delhaas</dc:creator>
<dc:creator>Kevin Vernooy</dc:creator>
<dc:creator>Joost Lumens</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study</dc:title>
<dc:identifier>pmid:39589540</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae718</dc:identifier>
</item>
<item>
<title>Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39589479/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 26:ehae766. doi: 10.1093/eurheartj/ehae766. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39589479/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39589479</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae766>10.1093/eurheartj/ehae766</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39589479</guid>
<pubDate>Tue, 26 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Markus Meyer</dc:creator>
<dc:date>2024-11-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?</dc:title>
<dc:identifier>pmid:39589479</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae766</dc:identifier>
</item>
<item>
<title>Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):1812-1814. doi: 10.1161/CIRCULATIONAHA.124.072172. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39585932</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11594480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">PMC11594480</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072172>10.1161/CIRCULATIONAHA.124.072172</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585932</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dongze Qin</dc:creator>
<dc:creator>Radheshyam Modanwal</dc:creator>
<dc:creator>Richard N Kitsis</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction</dc:title>
<dc:identifier>pmid:39585932</dc:identifier>
<dc:identifier>pmc:PMC11594480</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072172</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241128011632&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):e467. doi: 10.1161/CIRCULATIONAHA.124.070129. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241128011632&v=2.18.0.post9+e462414">39585931</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070129>10.1161/CIRCULATIONAHA.124.070129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585931</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Meng Zhang</dc:creator>
<dc:creator>Xudong Pan</dc:creator>
<dc:creator>Xiaoyan Zhu</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era"</dc:title>
<dc:identifier>pmid:39585931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070129</dc:identifier>
</item>





























</channel>
</rss>